Determining initial ocular comfort differences between 0.7% olopatadine and 0.035% ketotifen fumarate.

Purpose: To compare the ocular comfort at application of topical, over-the-counter, 0.7% olopatadine and 0.035% ketotifen fumarate anti-allergy eye drops.
Methods: This study recruited participants who were minimally symptomatic based upon Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire scores (≤3 units) and who had minimal between-eye inter-ocular comfort differences as judged by visual analog scale scores (VAS; ≤7 units). Baseline comfort was evaluated by eye with a VAS. One drop of 0.7% olopatadine or 0.035% ketotifen fumarate was then applied to the right eye with the alternative drop being immediately applied to the left eye. Participants were next evaluated with the same comfort VAS by eye at drop application, and then at 30 s, 1 min, and 2 min post-application. LogMAR visual acuities and bulbar conjunctival redness were evaluated pre- and post-drop application to judge initial changes.
Results: This study enrolled 159 participants who had a mean ± SD age of 26.3 ± 7.7 years, and 78.6% of the participants were female. The VAS found that the 0.7% olopatadine drop was more comfortable than the 0.035% ketotifen fumarate drop at all time-points. There were no between-eye differences in LogMAR visual acuities, yet bulbar redness was significantly less in 0.7% olopatadine treated eyes compared 0.035% ketotifen fumarate treated eyes.
Conclusion: This study found that topically applied 0.7% olopatadine drops were initially more comfortable than 0.035% ketotifen fumarate drops.
Competing Interests: Declaration of Competing Interest The authors have received research support from Abbvie Pharmaceuticals (CH, LRK, MC, RB, CL), Alcon Research, LLC (All), Allergan (CL, CH, MC, RB), Art Optical (ADP), Bausch & Lomb (ADP), Euclid Systems (ADP), Contamac (ADP), and National Eye Institute (ADP), and consultant for Alcon Research, LLC (ADP), Allergan (CL, CH, MC, RB), CooperVision (ADP), EpiTech (ADP), EyeGate Pharmaceuticals, Inc (ADP), Kala Pharmaceuticals (ADP), MacuLogix (CL), Nevakar Inc (ADP), Optikal Care Inc (ADP), RVL Pharmaceuticals, Inc (CL), Transitions (CL), and Transitions Optical (CL) over the past three years.
(Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)